ROIV Form 4: 665,159 shares sold; multiple option exercises noted
Rhea-AI Filing Summary
Insider transactions by Eric Venker at Roivant Sciences (ROIV) show multiple option exercises and open-market sales executed under a Rule 10b5-1 plan. Between 10/06/2025 and 10/08/2025, the reporting person exercised options at strike prices of $15.85, $7.45, and $3.85 and sold a total of 665,159 common shares at weighted-average prices reported up to $16.34. Following these transactions the filing reports beneficial ownership of 1,504,959 common shares. Several exercised option grants are described as fully vested or subject to stated vesting schedules.
Positive
- Use of a Rule 10b5-1 trading plan provides a pre-established compliance framework for the reported sales
- Options exercised were largely vested, allowing conversion without additional service contingencies
Negative
- Total reported sales of 665,159 shares between 10/06/2025 and 10/08/2025 reduced insider holdings materially
- Weighted-average sale prices varied up to $16.34, indicating sales at multiple price levels which may affect near-term float
Insights
TL;DR: Insider exercised vested options and sold 665,159 shares under a 10b5-1 plan over three days.
The reporting person converted multiple stock options into common shares at strikes of $15.85, $7.45, and $3.85, increasing share counts from option exercise while concurrently selling shares. Sales were effected pursuant to a Rule 10b5-1 trading plan adopted on 03/28/2025, with weighted-average sale prices disclosed up to $16.34.
Key dependencies include the 10b5-1 plan terms and the vesting status of awards (some fully vested, others with scheduled vesting). Monitor short-term dilution and insider ownership level of 1,504,959 shares as the primary near-term metric; any future planned sales under a continuing plan could further change ownership within weeks.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 10,307 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 128,295 | $0.00 | -- |
| Exercise | Common Shares | 10,307 | $15.85 | $163K |
| Exercise | Common Shares | 128,295 | $7.45 | $956K |
| Sale | Common Shares | 138,602 | $16.20 | $2.25M |
| Exercise | Stock Option (Right to Buy) | 67,171 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 107,131 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 180,859 | $0.00 | -- |
| Exercise | Common Shares | 67,171 | $15.85 | $1.06M |
| Exercise | Common Shares | 107,131 | $7.45 | $798K |
| Exercise | Common Shares | 180,859 | $3.85 | $696K |
| Sale | Common Shares | 355,161 | $16.15 | $5.74M |
| Exercise | Stock Option (Right to Buy) | 127,355 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 24,900 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 19,141 | $0.00 | -- |
| Exercise | Common Shares | 127,355 | $15.85 | $2.02M |
| Exercise | Common Shares | 24,900 | $7.45 | $186K |
| Exercise | Common Shares | 19,141 | $3.85 | $74K |
| Sale | Common Shares | 171,396 | $16.34 | $2.80M |
Footnotes (1)
- The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025. Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options are fully vested. Award of stock options to purchase Common Shares with a vesting commencement date of October 16, 2017. These options are fully vested. Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).
